abstract |
Histone deacetylases inhibitors (HDACIs) and compositions comprising the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed. In one aspect, the invention relates to a compound having the structure n nor a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof. In one embodiment of the invention, R 1 is ethyl; R 2 is 2-phenylethyl; R 3 is hydrogen; R 4 is fluoro; R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R 6 is hydrogen, or a salt thereof. In another embodiment of the invention, R 1 is ethyl; R 2 is 2-phenylethyl; R 3 is hydrogen; R 4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R 5 is chloro or fluoro; and R 6 is hydrogen, or a salt thereof. |